82 related articles for article (PubMed ID: 32808239)
1. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Kazmi S; Chatterjee D; Raju D; Hauser R; Kaufman PA
Breast Cancer Res Treat; 2020 Nov; 184(2):559-565. PubMed ID: 32808239
[TBL] [Abstract][Full Text] [Related]
2. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
Breast Cancer Res Treat; 2024 May; 205(1):201-210. PubMed ID: 38310616
[TBL] [Abstract][Full Text] [Related]
5. Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
Fumet JD; Wickre M; Jacquot JP; Bizollon MH; Melis A; Vanoli A; Viel E
BMC Cancer; 2018 Aug; 18(1):839. PubMed ID: 30126360
[TBL] [Abstract][Full Text] [Related]
6. Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?
Catania G; Malaguti P; Gasparro S; Cognetti F; Vidiri A; Fabi A
Oncology; 2018; 94 Suppl 1(Suppl 1):29-33. PubMed ID: 30041177
[TBL] [Abstract][Full Text] [Related]
7. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
[TBL] [Abstract][Full Text] [Related]
8. Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy.
Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
Breast Cancer (Dove Med Press); 2023; 15():855-865. PubMed ID: 38020049
[TBL] [Abstract][Full Text] [Related]
9. Eribulin in metastatic breast cancer: Real world data.
Fernández-Laguna CL; Maray I; Macia-Rivas L; Álvarez-Asteinza C; Fernández-Lastras S; Velasco Durántez V; Carbajales Álvarez M; Lozano-Blázquez A
Breast Dis; 2023; 42(1):349-360. PubMed ID: 38073367
[TBL] [Abstract][Full Text] [Related]
10. Activity of capecitabine for central nervous system metastases from breast cancer.
Gouveia MC; Hidalgo Filho CM; Moreno RA; Alves HCBR; Ayres AS; Testa L; Bonadio RC
Ecancermedicalscience; 2023; 17():1638. PubMed ID: 38414937
[TBL] [Abstract][Full Text] [Related]
11. Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.
Kaufman PA; Neuberger E; Schwartz NRM; Wang S; Liu Y; Hsu LI; Bartley K; Blahna MT; Pittner BT; Wong G; Anders C
Front Oncol; 2023; 13():1264861. PubMed ID: 37849811
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Chen C; Layman RM; Rugo HS
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958441
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study.
Huang W; Wang C; Wang L; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
Front Cell Dev Biol; 2024; 12():1313610. PubMed ID: 38481526
[No Abstract] [Full Text] [Related]
14. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer.
Shin J; Kim JY; Oh JM; Lee JE; Kim SW; Nam SJ; Park W; Park YH; Ahn JS; Im YH
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835414
[TBL] [Abstract][Full Text] [Related]
16. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
Celik A; Berg T; Jensen MB; Jakobsen E; Nielsen HM; Kümler I; Glavicic V; Jensen JD; Knoop A
Breast Cancer (Auckl); 2023; 17():11782234231203292. PubMed ID: 37810797
[TBL] [Abstract][Full Text] [Related]
17. Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months.
Manthri S; Sharma P; Mejbel HA; Singal S; Jaishankar D
Cureus; 2020 Feb; 12(2):e6980. PubMed ID: 32201658
[TBL] [Abstract][Full Text] [Related]
18. Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study.
Huppert LA; Fisch S; Tsopurashvili E; Somepalle SS; Salans M; Vasudevan HN; Jo Chien A; Majure M; Rugo HS; Balassanian R; Boreta L; Melisko ME
Breast Cancer Res Treat; 2024 Aug; 206(3):625-636. PubMed ID: 38888796
[TBL] [Abstract][Full Text] [Related]
19. Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.
Wickmann A; Kurte MS; Jeck J; Camacho L; Klinkhammer D; Kron F; Dengler R
Cost Eff Resour Alloc; 2024 Mar; 22(1):21. PubMed ID: 38459569
[TBL] [Abstract][Full Text] [Related]
20. Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.
Menis J; Twelves C
Breast Cancer (Dove Med Press); 2011 Aug; 3():101-11. PubMed ID: 24367180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
